Gene: PRDM5

11107
BCS2|PFM2
PR/SET domain 5
protein-coding
4q27
Ensembl:ENSG00000138738 MIM:614161 Vega:OTTHUMG00000132970 UniprotKB:Q9NQX1
NG_031862.2
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.821e-1 (AD)  6.930e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
WRN0.734
IMPACT0.725
GSTCD0.72
SLC35A30.708
PTPRG0.689
WDR350.688
UEVLD0.686
MCM90.684
SCAF110.683
TRDMT10.683

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
C7orf61-0.361
OR4F5-0.337
CLDN9-0.304
WFIKKN1-0.298
MIA-0.298
OR4F29-0.293
BNIPL-0.288
CELSR1-0.287
CNTD2-0.285
LBX2-0.277

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA"27188386
D020106AcrylamideAcrylamide results in increased expression of PRDM5 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of PRDM5 gene27153756
D000393Air PollutantsAir Pollutants results in decreased expression of PRDM5 mRNA23649983
C006780bisphenol Abisphenol A affects the expression of PRDM5 mRNA21786754
C006780bisphenol Abisphenol A affects the methylation of PRDM5 promoter27334623
C006780bisphenol Abisphenol A affects the expression of PRDM5 mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of PRDM5 mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of PRDM5 mRNA26079696
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in increased expression of PRDM5 mRNA26272509
D002737ChloropreneChloroprene results in increased expression of PRDM5 mRNA23125180
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of PRDM5 mRNA20938992
C012843cinnamic aldehydecinnamic aldehyde results in increased expression of PRDM5 mRNA19524605
D019327Copper SulfateCopper Sulfate results in decreased expression of PRDM5 mRNA19549813
C024629dimethyl phthalatedimethyl phthalate affects the expression of PRDM5 mRNA26924002
C118739entinostatentinostat results in decreased expression of PRDM5 mRNA27188386
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of PRDM5 mRNA20938992
C042720mercuric bromidemercuric bromide results in increased expression of PRDM5 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA"27188386
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of PRDM5 mRNA20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of PRDM5 mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of PRDM5 mRNA26011545
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of PRDM5 mRNA"26251327
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of PRDM5 mRNA25729387
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in decreased expression of PRDM5 mRNA21427059
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of PRDM5 mRNA20067830
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of PRDM5 mRNA19465110
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of PRDM5 mRNA25729387
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of PRDM5 mRNA"26743178
D014635Valproic AcidValproic Acid affects the expression of PRDM5 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of PRDM5 mRNA23179753|2718838
D014635Valproic AcidValproic Acid results in decreased expression of PRDM5 mRNA21427059

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IBA21873635  
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IDA17636019  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0001078transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IBA21873635  
GO:0001078transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IDA17636019  
GO:0003700DNA-binding transcription factor activity-IBA21873635  
GO:0005515protein binding-IPI17636019  
GO:0008168methyltransferase activity-IEA-  
GO:0031490chromatin DNA binding-IBA21873635  
GO:0043565sequence-specific DNA binding-IBA21873635  
GO:0043565sequence-specific DNA binding-IDA17636019  
GO:0044212transcription regulatory region DNA binding-IDA17636019  
GO:0046872metal ion binding-IEA-  
GO:0070491repressing transcription factor binding-IBA21873635  
GO:0070491repressing transcription factor binding-IDA17636019  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IDA17636019  
GO:0000278mitotic cell cycle-IMP17636019  
GO:0006351transcription, DNA-templated-IEA-  
GO:0016575histone deacetylation-IBA21873635  
GO:0016575histone deacetylation-IMP17636019  
GO:0045892negative regulation of transcription, DNA-templated-IDA17636019  
GO:0051567histone H3-K9 methylation-IBA21873635  
GO:0051567histone H3-K9 methylation-IDA17636019  
GO:1990830cellular response to leukemia inhibitory factor-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA17636019  
GO:0005730nucleolus-IDA-  
GO:0016604nuclear body-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24395656Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma. (2014 May)Tan SXTumour Biol